Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Summary: Background: Obesity has reached epidemic proportions, with >40% of the US population affected. Although traditionally managed by lifestyle modification, and less frequently by bariatric therapies, there are significant pharmacological advancements. Aims: To conduct a narrative review of the neurohormonal and physiological understanding of weight gain and obesity, and the development, clinical testing, indications, expected clinical outcomes, and associated risks of current FDA‐approved and upcoming anti‐obesity medications (AOMs). Methods: We conducted a comprehensive review in PubMed for articles on pathophysiology and complications of obesity, including terms ‘neurohormonal’, ‘obesity’, ‘incretin’, and ‘weight loss’. Next, we searched for clinical trial data of all FDA‐approved AOMs, including both the generic and trade names of orlistat, phentermine/topiramate, bupropion/naltrexone, liraglutide, and semaglutide. Additional searches were conducted for tirzepatide and retatrutide ‐ medications expecting regulatory approval. Searches included combinations of terms related to mechanism of action, indications, side effects, risks, and future directions. Results: We reviewed the pathophysiology of obesity, including specific role of incretins and glucagon. Clinical data supporting the use of various FDA‐approved medications for weight loss are presented, including placebo‐controlled or, when available, head‐to‐head trials. Beneficial metabolic effects, including impact on liver disease, adverse effects and risks of medications are discussed, including altered gastrointestinal motility and risk for periprocedural aspiration. Conclusion: AOMs have established efficacy and effectiveness for weight loss even beyond 52 weeks. Further pharmacological options, such as dual and triple incretins, are probable forthcoming additions to clinical practice for combating obesity and its metabolic consequences such as metabolic dysfunction‐associated steatotic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Shi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., Chen, Z., Xu, S., Shen, Y., Ge, L., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01640-8 · Cited by 279
RetractedOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“24 This greater weight loss efficacy is attributed to effects of AOMs on appetite and reg - ulation of food intake.”
BackgroundObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 1×
“94 A subgroup analysis from the SURPASS program was performed in Hispanic/ Latino vs non-Hispanic/Latino with T2DM, and there was no sig - nificant difference between groups taking tirzepatide in regards to safety outcomes, weight reduction and HbA1c improvement.”
MethodA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Diagnosis and Management of Infertility: A Review
Carson, S. A., & Kallen, A. N. (2021) · JAMA · doi:10.1001/jama.2021.4788 · Cited by 1,294 · cited 2×
“21 Moreover, analysis of the placebo-controlled trials of oral semaglutide (PIONEER 1, 4, 5, and 8) 48 demonstrated that gastro - intestinal adverse effects (predominantly nausea, and presumably a surrogate for delayed GE) contributed to a small, but significant proportion of the estimated…”
BackgroundSjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174 · cited 2×
“23 Its novelty arises from its additional agonism to the glucagon re - ceptor that is known to increase hepatic glucose, and thought to increase efficacy by reducing energy intake and enhancing energy expenditure.”
BackgroundWilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947 · cited 1×
“49 52 However, by the end of the second year of follow-up, the TBWL was about 6%–8% 43 or 5%, 53 and additional TBWL beyond lifestyle interventions was estimated at about 3%.”
BackgroundMagkos, F., Fraterrigo, G., Yoshino, J., Luecking, C., Kirbach, K., Kelly, S. C., de las Fuentes, L., He, S., Okunade, A. L., Patterson, B. W., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.005 · Cited by 886 · cited 1×
“102 In a phase 2 placebo-controlled trial with biopsy confirmed MASH, SQ semaglutide 0.1 mg/day showed histological fibro - sis stage improvement 103 and in another phase 2 RCT with MRI-confirmed MASLD, semaglutide 0.4 mg daily significantly reduced liver fat content, without difference in liver…”
BackgroundInfluentialLong-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865
Self-citationAronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860 · cited 1×
“116 These observations emphasise the need for chronic management of obesity with lifestyle interventions, as these medica - tions do not revert the pathogenesis of obesity.”
Backgroundon behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 1×
“Aside from a single study comparing the weight loss outcomes for liraglutide as compared to orlistat, 99 there have been no head- to-head RCTs of incretin and non-incretin medications for obesity.”
BackgroundQuek, J., Chan, K. E., Wong, Z. Y., Tan, C., Tan, B., Lim, W. H., Tan, D. J. H., Tang, A. S. P., Tay, P., Xiao, J., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00317-x · Cited by 749
Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594 · cited 1×
“92 A more recent phase 3 superiority RCT of non-diabetic, over - weight or obese patients evaluated oral semaglutide at a higher dose of 50 mg once daily and showed an estimated TBWL of 12.7% from the baseline over 68 weeks compared to placebo.”
BackgroundInfluentialWadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Alhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · cited 1×
“72 Studies have suggested an inverse relationship between GLP-1 serum levels and body weight and the obesity phenotype.”
BackgroundGastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0234 · Cited by 501 · cited 1×
“18,20,67,68 The Contrave Obesity Research (COR)-”
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02597-w · Cited by 442
Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01185-6 · Cited by 431
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429 · cited 1×
“139 Its benefits should always be taken into consideration, especially if they outweigh the risks.”
BackgroundThe circadian regulation of food intake
Challet, E. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0210-x · Cited by 428 · cited 1×
“27 However, the mechanisms of food regulation extend outside the central nervous system (CNS), and gastrointestinal and periph - eral neurohormonal mechanisms are key.”
BackgroundCapehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394 · cited 1×
“Patients should be educated on side effects and recommended to eat smaller meals and stop when feeling full 11,140 Treatment goals should be individualised for each patient; how - ever, lifestyle modifications leading to 5%–10% weight loss including increasing physical activity and/or a low-calorie…”
BackgroundAGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347
Kadowaki, T., Isendahl, J., Khalid, U., Lee, S. Y., Nishida, T., Ogawa, W., Tobe, K., Yamauchi, T., & Lim, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00008-0 · Cited by 330
Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316 · cited 1×
“97 It has shown significant TBWL up to 24% of their baseline weight at 48 weeks in patients receiving the maximum 12 mg dose, being comparable to the efficacy of bariatric surgery.”
BackgroundCentral and peripheral GLP-1 systems independently suppress eating
Brierley, D. I., Holt, M. K., Singh, A., de Araujo, A., McDougle, M., Vergara, M., Afaghani, M. H., Lee, S. J., Scott, K., Maske, C., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00344-4 · Cited by 265
Yan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260
Silveira, S. Q., da Silva, L. M., de Campos Vieira Abib, A., de Moura, D. T. H., de Moura, E. G. H., Santos, L. B., Ho, A. M.-H., Nersessian, R. S. F., Lima, F. L. M., Silva, M. V., et al. (2023) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2023.111091 · Cited by 259
Armstrong, M. J., Houlihan, D. D., Rowe, I. A., Clausen, W. H. O., Elbrønd, B., Gough, S. C. L., Tomlinson, J. W., & Newsome, P. N. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12149 · Cited by 250 · cited 2×
“Similarly, significant weight loss and non-invasive liver parameters improvement have been observed with subsequent analysis of the LEAD trial with liraglutide, showing improvement in serum ALT. 105 Later, a phase 2 RCT by the same authors showed as - sociation between liraglutide and histological resolution compared…”
BackgroundKuchay, M. S., Krishan, S., Mishra, S. K., Choudhary, N. S., Singh, M. K., Wasir, J. S., Kaur, P., Gill, H. K., Bano, T., Farooqui, K. J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05265-7 · Cited by 249
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
Acosta, A., Camilleri, M., Abu Dayyeh, B., Calderon, G., Gonzalez, D., McRae, A., Rossini, W., Singh, S., Burton, D., & Clark, M. M. (2021) · Obesity · doi:10.1002/oby.23120 · Cited by 222 · cited 1×
“…ad libitum meal, or inadequate satisfaction 30 minutes after standard meal ingestion (‘hungry brain phenotype’) appear to have a significant response to treatment with phentermine topiramate 65 (In a real world clinical experience, this medication was associated with 12.0% TBWL at 12 months 16 ).”
BackgroundInfluentialSelf-citationBlundell, J. E., & Finlayson, G. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.04.021 · Cited by 198
Umapathysivam, M. M., Lee, M. Y., Jones, K. L., Annink, C. E., Cousins, C. E., Trahair, L. G., Rayner, C. K., Chapman, M. J., Nauck, M. A., Horowitz, M., et al. (2014) · Diabetes · doi:10.2337/db13-0893 · Cited by 193 · cited 2×
“120 Additionally, delayed GE has been re - ported 84,98,121 and reduced accommodation 122 has been observed.”
BackgroundKadouh, H., Chedid, V., Halawi, H., Burton, D. D., Clark, M. M., Khemani, D., Vella, A., Acosta, A., & Camilleri, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz140 · Cited by 166
Self-citationHanefeld, M., & Sachse, G. (2002) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00237.x · Cited by 151 · cited 2×
“45,53 Improvement in abdominal visceral adipose tissue mass was documented with orlistat 60 mg three times daily as compared to placebo over 24 weeks.”
BackgroundKobori, T., Onishi, Y., Yoshida, Y., Tahara, T., Kikuchi, T., Kubota, T., Iwamoto, M., Sawada, T., Kobayashi, R., Fujiwara, H., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14005 · Cited by 144
Khoo, J., Hsiang, J. C., Taneja, R., Koo, S., Soon, G., Kam, C. J., Law, N., & Ang, T. (2019) · Liver International · doi:10.1111/liv.14065 · Cited by 136
Maselli, D., Atieh, J., Clark, M. M., Eckert, D., Taylor, A., Carlson, P., Burton, D. D., Busciglio, I., Harmsen, W. S., Vella, A., et al. (2022) · Obesity · doi:10.1002/oby.23481 · Cited by 136 · cited 4×
“21 Moreover, analysis of the placebo-controlled trials of oral semaglutide (PIONEER 1, 4, 5, and 8) 48 demonstrated that gastro - intestinal adverse effects (predominantly nausea, and presumably a surrogate for delayed GE) contributed to a small, but significant proportion of the estimated…”
BackgroundMethodInfluentialSelf-citationSherwin, M., Hamburger, J., Katz, D., & DeMaria, S. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02549-5 · Cited by 132
Kabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity
Jensterle, M., Ferjan, S., Ležaič, L., Sočan, A., Goričar, K., Zaletel, K., & Janez, A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14944 · Cited by 102
Vosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L. J., Davitkov, P., Murad, M. H., & Camilleri, M. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101213 · Cited by 97 · cited 1×
“93 Another systematic review and meta-analysis con - ducted in patients with obesity with or without diabetes found that non-T2DM patients achieved greater mean weight loss and nausea could have contributed to excess weight loss (coefficient: 0.12, 95% CI: 0.06–0.17).”
BackgroundInfluentialSelf-citationExenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study
Acosta, A., Camilleri, M., Burton, D., O'Neill, J., Eckert, D., Carlson, P., & Zinsmeister, A. R. (2015) · Physiological Reports · doi:10.14814/phy2.12610 · Cited by 78 · cited 1×
“120 Additionally, delayed GE has been re - ported 84,98,121 and reduced accommodation 122 has been observed.”
BackgroundSelf-citationStark, J. E., Cole, J. L., Ghazarian, R. N., & Klass, M. J. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280211055804 · Cited by 77
Vosoughi, K., Salman Roghani, R., & Camilleri, M. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100456 · Cited by 65 · cited 1×
“83 The question whether gastrointestinal adverse events such as nausea contributed to weight reduction has been challenged.”
BackgroundSelf-citationQuast, D. R., Schenker, N., Menge, B. A., Nauck, M. A., Kapitza, C., & Meier, J. J. (2020) · Diabetes Care · doi:10.2337/dc20-0720 · Cited by 64
Anazco, D., Fansa, S., Hurtado, M. D., Camilleri, M., & Acosta, A. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.11.024 · Cited by 58
Self-citationCalderon, G., Gonzalez-Izundegui, D., Shan, K. L., Garcia-Valencia, O. A., Cifuentes, L., Campos, A., Collazo-Clavell, M. L., Shah, M., Hurley, D. L., Abu Lebdeh, H. S., et al. (2022) · International Journal of Obesity · doi:10.1038/s41366-021-01019-6 · Cited by 52
Self-citationSmith, S. R., Stenlof, K. S., Greenway, F. L., McHutchison, J., Schwartz, S. M., Dev, V. B., Berk, E. S., & Kapikian, R. (2011) · Obesity · doi:10.1038/oby.2011.143 · Cited by 51 · cited 1×
“56 Unfortunately, side effects from orlistat are quite common and predictable, due to inhibition of fat absorption: diarrhoea, faecal urgency, oily spotting in the toilet, increased flatus, abdominal pain, and in extreme situations, faecal incontinence, 57 as well as vitamin and mineral…”
BackgroundMuratori, F., Vignati, F., Di Sacco, G., Gavazzi, L., Pellegrino, D., & Del Prete, M. (2022) · Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity · doi:10.1007/s40519-022-01403-9 · Cited by 49
Incretin-based drugs and intestinal obstruction: A pharmacovigilance study
Gudin, B., Ladhari, C., Robin, P., Laroche, M.-L., Babai, S., Hillaire-Buys, D., & Faillie, J.-L. (2020) · Therapies · doi:10.1016/j.therap.2020.02.024 · Cited by 37
The novel GIP , GLP ‐1 and glucagon receptor agonist retatrutide delays gastric emptying
Urva, S., O'Farrell, L., Du, Y., Loh, M. T., Hemmingway, A., Qu, H., Alsina‐Fernandez, J., Haupt, A., Milicevic, Z., & Coskun, T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15167 · Cited by 28 · cited 3×
“120 Additionally, delayed GE has been re - ported 84,98,121 and reduced accommodation 122 has been observed.”
BackgroundKolotkin, R. L., Gadde, K. M., Peterson, C. A., & Crosby, R. D. (2016) · Quality of Life Research · doi:10.1007/s11136-015-1153-x · Cited by 24
Cited by
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
“Similarly, the evaluation of gastrointestinal symptoms such as nausea, vomiting, and diarrhea, which occur frequently with GLP-1RAs (42) and have a major influence on the adherence to such treatment over time, have often been assessed in clinical trials solely via participant self-report, which is…”
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
Jalleh, R. J., Rayner, C. K., Hausken, T., Jones, K. L., Camilleri, M., & Horowitz, M. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00188-2 · Cited by 144
Self-citationChristensen, S., Robinson, K., Thomas, S., & Williams, D. R. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100121 · Cited by 108
“Physiologically, GLP-1 and GIP/GLP-1 RAs stimulate insulin secretion and inhibit glucagon release in a dose-dependent manner and bind to the appetite-regulating centers in the hindbrain, hypothalamus, and mesolimbic pathway [12 – 15].”
BackgroundScott Butsch, W., Sulo, S., Chang, A. T., Kim, J. A., Kerr, K. W., Williams, D. R., Hegazi, R., Panchalingam, T., Goates, S., & Heymsfield, S. B. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100186 · Cited by 58
“Although GLP-1RAs are thought to inhibit glucagon release and stimulate insulin secretion while interacting with appetite-regulating centers in the hindbrain, hypothalamus, and mesolimbic pathway, the precise mechanisms of this class of drugs remain incompletely understood [15 – 17].”
(2026) · doi:10.1007/s13668-026-00777-x · Cited by 10
Metadata
- Authors
- Lupianez‐Merly, C., Dilmaghani, S., Vosoughi, K., & Camilleri, M.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2024-01-02
- Volume
- 59
- Issue
- 4
- Pages
- 475-491
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W4390540452
- Cited by
- 40
- References
- 71
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.